Compare Boston Scientific Corporation (BSX) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs HSBC Holdings plc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while HSBC Holdings plc trades at $99.75 (market cap $337.30B). The key difference: HSBC Holdings plc is far larger — about 5.1× Boston Scientific Corporation's market cap, and HSBC Holdings plc pays a 3.78% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | HSBC | |
|---|---|---|
Market Cap | $66.37B | $337.30B |
Sector | Health | Technology |
52-Week High | $108.14 | $99.25 |
52-Week Low | $42.63 | $61.30 |
Enterprise Value | $75.94B | — |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
HSBC trades at $98.09, down 1.01% today but near its 52-week high of $99.47. Technical indicators show a bullish trend with strong moving average support. The bank reported $71.02B revenue and $22.29B net income for 2025, maintaining a robust 30.81% net margin. Recent news highlights strategic moves including AI partnerships with Google Cloud and potential divestitures of non-core units like its Turkey business.
HSBC presents a balanced investment case with steady profitability and strategic refocusing, but faces risks from global economic sensitivity and regulatory challenges. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
